In this review, we aimed to summarize the mechanisms of actions of various ICIs, namely PD-1 inhibitors, PD-L1 inhibitors, and anti-CTLA-4 antibodies; mechanisms that cause irAEs; cases of ICI use in gynecological cancer; and clinical symptoms and appropriate management of various irAEs. The gene discussed is CTLA4; the disease is female reproductive organ cancer.